國產(chǎn)心臟支架贏得國際醫(yī)學(xué)界的認(rèn)可

A Chinese-made heart stent has won recognition from the international medical community, with clinical trial results published online in the prestigious medical journal The Lancet.

一種中國制造的心臟支架獲得了國際醫(yī)學(xué)界的認(rèn)可，其臨床試驗(yàn)結(jié)果發(fā)表在著名醫(yī)學(xué)雜志《柳葉刀》的網(wǎng)站上。

Named Firehawk, the drug-eluting stent was developed by MicroPort Scientific Corporation, a Chinese healthcare company, to treat patients with coronary artery disease.

這種藥物洗脫支架被命名為火鷹(Firehawk)，由中國醫(yī)療保健企業(yè)微創(chuàng)醫(yī)療科學(xué)有限公司研發(fā)，用于治療冠心病患者。

The metal stent is 86 microns thick, which is roughly the diameter of a human hair. It contains drugs in micro grooves engraved by lasers on the surface, which prevents the drug from leaking during the transportation of the stent.

該金屬支架有86微米厚，大概是人類頭發(fā)的直徑。它包含藥物在表面激光雕刻的微槽中，防止藥物在運(yùn)送支架時泄漏。

Clinical trials were conducted in 21 hospitals in 10 European countries from December 2015 to October 2016. Altogether 1,653 patients from the UK, France, Spain, Italy, Belgium, the Netherlands, Poland, Germany, Austria, and Denmark were implanted with the stent.

從2015年12月至2016年10月，臨床試驗(yàn)在10個歐洲國家的21家醫(yī)院進(jìn)行。共有1653名來自英國、法國、西班牙、意大利、比利時、荷蘭、波蘭、德國、奧地利和丹麥的患者植入了這種支架。

According to William Wijns, a professor from the National University of Ireland Galway who led the clinical study, this is the first time that China's medical device went through randomized clinical trials in Europe on such a scale.

領(lǐng)導(dǎo)臨床研究的愛爾蘭戈爾韋國立大學(xué)教授威廉·魏恩斯表示，這是中國醫(yī)療設(shè)備首次在歐洲進(jìn)行如此規(guī)模的隨機(jī)臨床試驗(yàn)。

Results showed that the safety and clinical efficacy of this stent could rival the Xience stent, one of the world's leading drug-eluting stents.

結(jié)果表明，該支架的安全性和臨床療效可以與世界上領(lǐng)先的藥物洗脫支架之一的Xience支架相媲美。

In addition, its unique design could save drug dosages and help prevent side effects such as thrombus after implantation.

此外，其獨(dú)特的設(shè)計可以節(jié)省藥物劑量，并有助于防止植入后血栓等副作用。